Banque Cantonale Vaudoise’s Black Diamond Therapeutics BDTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$278K	Buy	+147,221	New	+$288K	0.01%	568

Other funds holding BDTX

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Banque Cantonale Vaudoise's BDTX Position: Q3 2026 in Review

Banque Cantonale Vaudoise opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 147,221 shares worth $278K. The stake represents 0.01% of the portfolio and ranks #568 among its holdings.

52 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

Banque Cantonale Vaudoise held 147,221 shares of Black Diamond Therapeutics worth $278K as of Q3 2026.
Black Diamond Therapeutics was a new Banque Cantonale Vaudoise position in Q3 2026.
Black Diamond Therapeutics made up 0.01% of Banque Cantonale Vaudoise's portfolio in Q3 2026, its #568 holding.
52 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2026, filed 12 Nov 2026.